A Phase II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors

NCT06895928 Phase 2 RECRUITING

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.

Details

Lead sponsor	Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase	Phase 2
Status	RECRUITING
Enrolment	400
Start date	2025-03-28
Completion	2028-12

Conditions

• Advanced Solid Tumors

Interventions

• SHR-A2102
• Bevacizumab Injection
• Adebelimab Injection
• Ametinib Mesylate Tablets
• Osimertinib Mesylate Tablets

Primary outcomes

• Adverse events (AEs) — From day 1 to 90 days after the last dose.
• Serious adverse events (SAEs) — From day 1 to 90 days after the last dose.
• Objective response rate (ORR) — About 2 years.

Countries

China